Financhill
Sell
26

ELVN Quote, Financials, Valuation and Earnings

Last price:
$20.68
Seasonality move :
-4.5%
Day range:
$19.74 - $21.29
52-week range:
$13.30 - $30.03
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.51x
Volume:
947K
Avg. volume:
618.9K
1-year change:
-4.88%
Market cap:
$1B
Revenue:
--
EPS (TTM):
-$1.92

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ELVN
Enliven Therapeutics
-- -$0.42 -- -1.96% $41.00
AIM
AIM ImmunoTech
-- -$0.09 -23.08% -53.85% $4.50
CVM
CEL-SCI
-- -- -- -- $8.00
ERNA
Ernexa Therapeutics
-- -- -- -- --
IBIO
iBio
$66.7K -$0.34 -61.9% -62.3% $4.87
IGC
IGC Pharma
$326K -$0.03 3.39% -50% $3.88
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ELVN
Enliven Therapeutics
$20.64 $41.00 $1B -- $0.00 0% --
AIM
AIM ImmunoTech
$0.04 $4.50 $2.8M -- $0.00 0% 13.27x
CVM
CEL-SCI
$2.52 $8.00 $7.6M -- $0.00 0% --
ERNA
Ernexa Therapeutics
$1.98 -- $14.6M -- $0.00 0% 6.55x
IBIO
iBio
$0.74 $4.87 $12.2M -- $0.00 0% --
IGC
IGC Pharma
$0.31 $3.88 $24.5M -- $0.00 0% 18.48x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ELVN
Enliven Therapeutics
-- 0.116 -- --
AIM
AIM ImmunoTech
48.41% 0.745 17.25% 0.71x
CVM
CEL-SCI
-- -0.752 -- --
ERNA
Ernexa Therapeutics
-- -0.056 -- 0.74x
IBIO
iBio
5.96% 0.733 3.92% 1.49x
IGC
IGC Pharma
2.1% 0.356 0.51% 0.21x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ELVN
Enliven Therapeutics
-- -$31.7M -- -- -- -$24.1M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
CVM
CEL-SCI
-- -$6.4M -- -- -- -$4.4M
ERNA
Ernexa Therapeutics
-- -$2.7M -7188.35% -- -226500% -$2.1M
IBIO
iBio
-- -$4.9M -83.08% -110.9% -2153.5% -$3.1M
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M

Enliven Therapeutics vs. Competitors

  • Which has Higher Returns ELVN or AIM?

    AIM ImmunoTech has a net margin of -- compared to Enliven Therapeutics's net margin of -10571.43%. Enliven Therapeutics's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    ELVN
    Enliven Therapeutics
    -- -$0.57 --
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About ELVN or AIM?

    Enliven Therapeutics has a consensus price target of $41.00, signalling upside risk potential of 98.64%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Enliven Therapeutics, analysts believe AIM ImmunoTech is more attractive than Enliven Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ELVN
    Enliven Therapeutics
    8 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is ELVN or AIM More Risky?

    Enliven Therapeutics has a beta of 0.831, which suggesting that the stock is 16.932% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

  • Which is a Better Dividend Stock ELVN or AIM?

    Enliven Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enliven Therapeutics pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ELVN or AIM?

    Enliven Therapeutics quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Enliven Therapeutics's net income of -$28.5M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Enliven Therapeutics's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enliven Therapeutics is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ELVN
    Enliven Therapeutics
    -- -- -- -$28.5M
    AIM
    AIM ImmunoTech
    13.27x -- $35K -$3.7M
  • Which has Higher Returns ELVN or CVM?

    CEL-SCI has a net margin of -- compared to Enliven Therapeutics's net margin of --. Enliven Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ELVN
    Enliven Therapeutics
    -- -$0.57 --
    CVM
    CEL-SCI
    -- -$2.40 --
  • What do Analysts Say About ELVN or CVM?

    Enliven Therapeutics has a consensus price target of $41.00, signalling upside risk potential of 98.64%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 9424.76%. Given that CEL-SCI has higher upside potential than Enliven Therapeutics, analysts believe CEL-SCI is more attractive than Enliven Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ELVN
    Enliven Therapeutics
    8 0 0
    CVM
    CEL-SCI
    1 0 0
  • Is ELVN or CVM More Risky?

    Enliven Therapeutics has a beta of 0.831, which suggesting that the stock is 16.932% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

  • Which is a Better Dividend Stock ELVN or CVM?

    Enliven Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enliven Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ELVN or CVM?

    Enliven Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Enliven Therapeutics's net income of -$28.5M is lower than CEL-SCI's net income of -$6.6M. Notably, Enliven Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enliven Therapeutics is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ELVN
    Enliven Therapeutics
    -- -- -- -$28.5M
    CVM
    CEL-SCI
    -- -- -- -$6.6M
  • Which has Higher Returns ELVN or ERNA?

    Ernexa Therapeutics has a net margin of -- compared to Enliven Therapeutics's net margin of -575900%. Enliven Therapeutics's return on equity of -- beat Ernexa Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ELVN
    Enliven Therapeutics
    -- -$0.57 --
    ERNA
    Ernexa Therapeutics
    -102.13% -$2.25 $1.7M
  • What do Analysts Say About ELVN or ERNA?

    Enliven Therapeutics has a consensus price target of $41.00, signalling upside risk potential of 98.64%. On the other hand Ernexa Therapeutics has an analysts' consensus of -- which suggests that it could grow by 45354.52%. Given that Ernexa Therapeutics has higher upside potential than Enliven Therapeutics, analysts believe Ernexa Therapeutics is more attractive than Enliven Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ELVN
    Enliven Therapeutics
    8 0 0
    ERNA
    Ernexa Therapeutics
    0 0 0
  • Is ELVN or ERNA More Risky?

    Enliven Therapeutics has a beta of 0.831, which suggesting that the stock is 16.932% less volatile than S&P 500. In comparison Ernexa Therapeutics has a beta of 5.300, suggesting its more volatile than the S&P 500 by 429.973%.

  • Which is a Better Dividend Stock ELVN or ERNA?

    Enliven Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ernexa Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enliven Therapeutics pays -- of its earnings as a dividend. Ernexa Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ELVN or ERNA?

    Enliven Therapeutics quarterly revenues are --, which are smaller than Ernexa Therapeutics quarterly revenues of $1K. Enliven Therapeutics's net income of -$28.5M is lower than Ernexa Therapeutics's net income of -$8.2M. Notably, Enliven Therapeutics's price-to-earnings ratio is -- while Ernexa Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enliven Therapeutics is -- versus 6.55x for Ernexa Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ELVN
    Enliven Therapeutics
    -- -- -- -$28.5M
    ERNA
    Ernexa Therapeutics
    6.55x -- $1K -$8.2M
  • Which has Higher Returns ELVN or IBIO?

    iBio has a net margin of -- compared to Enliven Therapeutics's net margin of -2182%. Enliven Therapeutics's return on equity of -- beat iBio's return on equity of -110.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    ELVN
    Enliven Therapeutics
    -- -$0.57 --
    IBIO
    iBio
    -- -$0.49 $14.8M
  • What do Analysts Say About ELVN or IBIO?

    Enliven Therapeutics has a consensus price target of $41.00, signalling upside risk potential of 98.64%. On the other hand iBio has an analysts' consensus of $4.87 which suggests that it could grow by 557.66%. Given that iBio has higher upside potential than Enliven Therapeutics, analysts believe iBio is more attractive than Enliven Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ELVN
    Enliven Therapeutics
    8 0 0
    IBIO
    iBio
    3 0 0
  • Is ELVN or IBIO More Risky?

    Enliven Therapeutics has a beta of 0.831, which suggesting that the stock is 16.932% less volatile than S&P 500. In comparison iBio has a beta of 0.936, suggesting its less volatile than the S&P 500 by 6.426%.

  • Which is a Better Dividend Stock ELVN or IBIO?

    Enliven Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enliven Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ELVN or IBIO?

    Enliven Therapeutics quarterly revenues are --, which are smaller than iBio quarterly revenues of $200K. Enliven Therapeutics's net income of -$28.5M is lower than iBio's net income of -$4.9M. Notably, Enliven Therapeutics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enliven Therapeutics is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ELVN
    Enliven Therapeutics
    -- -- -- -$28.5M
    IBIO
    iBio
    -- -- $200K -$4.9M
  • Which has Higher Returns ELVN or IGC?

    IGC Pharma has a net margin of -- compared to Enliven Therapeutics's net margin of -711.67%. Enliven Therapeutics's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    ELVN
    Enliven Therapeutics
    -- -$0.57 --
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
  • What do Analysts Say About ELVN or IGC?

    Enliven Therapeutics has a consensus price target of $41.00, signalling upside risk potential of 98.64%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1162.22%. Given that IGC Pharma has higher upside potential than Enliven Therapeutics, analysts believe IGC Pharma is more attractive than Enliven Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ELVN
    Enliven Therapeutics
    8 0 0
    IGC
    IGC Pharma
    2 0 0
  • Is ELVN or IGC More Risky?

    Enliven Therapeutics has a beta of 0.831, which suggesting that the stock is 16.932% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.452, suggesting its more volatile than the S&P 500 by 45.212%.

  • Which is a Better Dividend Stock ELVN or IGC?

    Enliven Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enliven Therapeutics pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ELVN or IGC?

    Enliven Therapeutics quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. Enliven Therapeutics's net income of -$28.5M is lower than IGC Pharma's net income of -$1.8M. Notably, Enliven Therapeutics's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enliven Therapeutics is -- versus 18.48x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ELVN
    Enliven Therapeutics
    -- -- -- -$28.5M
    IGC
    IGC Pharma
    18.48x -- $257K -$1.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Robinhood Stock Keep Going Up?
Will Robinhood Stock Keep Going Up?

Commission-free online brokerage Robinhood (NASDAQ:HOOD) has served up massive gains…

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
92
BGL alert for Jul 3

Blue Gold [BGL] is down 20.3% over the past day.

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 1.3% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is up 0.3% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock